source
- Boulevard starts up with $65M to pursue targeted autoimmune drugsCo-founded by pioneering researcher Georg Schett and ex-Sanofi CSO Frank Nestle, the startup is advancing a trio of multifaceted antibodies with the potential to treat several immune diseases.BioPharma Dive · 1h ago↗ source
- Epicrispr raises $90 million to push epigenetic editing drug EPI-321 for rare muscle disorder FSHDEpicrispr Biotechnologies announced a $90 million Series C financing to accelerate development of its epigenetic editing therapy EPI-321 for facioscapulohumeral muscular dystrophy (FSHD), a rare ge…